欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (5): 552-556.

• 定量药理学 • 上一篇    下一篇

盐酸克林霉素棕榈酸酯咀嚼片人体生物等效性研究

石小鹏, 王志睿, 杨志福, 吴寅, 陈苏宁, 金鑫, 文爱东   

  1. 第四军医大学西京医院药剂科, 西安710032, 陕西
  • 收稿日期:2008-01-15 修回日期:2008-05-22 发布日期:2020-11-09
  • 通讯作者: 文爱东, 男, 主任药师, 硕士生导师, 从事临床药学、临床药理学研究。Tel:029-84773636 E-mail:adwen @fmmu. edu. cn
  • 作者简介:石小鹏, 女, 主管药师, 从事临床药理学研究。Tel:029-84775476 E-mail:shixp @fmmu. edu. cn

Bioequivalence study of clindamycin palmitate hydrochloride chewable tablets in healthy volunteers

SHI Xiao-peng, WANG Zhi-rui, YANG Zhi-fu, WU Yin, CHEN Su-ning, JIN Xin, WEN Ai-dong   

  1. Department of Pharmacy, Xijing Hospital of Fourth Military Medical University, Xi' an 710032, Shaanxi, China
  • Received:2008-01-15 Revised:2008-05-22 Published:2020-11-09

摘要: 目的:评价单剂量口服盐酸克林霉素棕榈酸酯咀嚼片与参比分散片在健康人体中药代动力学及其生物等效性特征。方法:20 名男性健康志愿受试者, 口服盐酸克林霉素棕榈酸酯受试制剂和参比制剂600 mg, 用双周期交叉设计自身对照试验方法, 以液相色谱法测定服药后不同时刻的血药浓度。结果:按该方法测得的克林霉素血药浓度的最低定量限为0.125 μg/mL (r =0. 999) 。受试制剂与参比制剂的主要药代动力学参数Cmax分别为(4. 5 ±1. 4)、 (4. 6 ±1. 4) μg/mL;tmax分别为(0. 83 ±0. 33)、 (0. 90 ±0. 29) h; t1/2 分别为(2. 3 ± 0. 7)、 (2. 3 ±0. 7) h; AUC0→t 分别为(16 ±6)、 (17 ±6) μg·mL-1 ·h; AUC0→∞分别为(17 ±6)、 (18 ± 6) μg·mL-1·h, 各参数间比较差异无统计学意义(P >0. 05) 。结论:等效性分析受试制剂的相对生物利用度(F) 为96. 3%, 统计学结果显示两制剂具有生物等效性。

关键词: 克林霉素, 生物等效性, 高效液相色谱法

Abstract: AIM:To compare the pharmacokinetics and relative bioequivalence of chewable tablet of clindamycin palmitate hydrochloride with that of dispersible tablet. METHODS:An open randomized and two-period crossover study with a one week washout interval was performed in 20 healthy volunteers. Concentrations of clindamycin in plasma were assayed by High Performance Liquid Chromatography method after a single oral dose of 600 mg of the tested or the reference tablets. RESULTS:Limit of quantification was accepted as 0.125 μg/mL (r =0. 999). The main pharmacokinetic parameters of the test and the reference formulations were as follows: Cmax were (4. 5 ±1. 4) and (4. 6 ±1. 4) μg/mL;tmax were (0. 83 ±0. 33) and (0. 90 ±0. 29) h; t1/2 were (2. 3 ±0. 7) and (2. 3 ±0. 7) h; AUC0→t were (16 ±6) and (17 ±6) μg·mL-1·h; AUC0→∞ were (17 ±6) and (18 ±6) μg·mL-1·h. There was no significant difference between the parameters of two tablets. CONCLUSION: The relative bioavailability of the test tablet to reference tablet was 96. 3% .The results of the statistical analysis show that the two formulations are bioequivalent.

Key words: clindamycin, bioequivalence, HPLC

中图分类号: